The continuous research and development in the field of non-small cell lung cancer has helped the medical fraternity develop new drugs for targeting specific types of changes that cancer brings in. Non-small cell lung cancer (NSCLC), which is the second most common type of cancer seen across the globe, is also being studied for developing better therapies. It is also the most dangerous form of cancer, as it metastasizes into tissues and bones, leaving barely any time for reaction. The increasing incidence of non-small cell lung cancer, growing awareness about it, and government initiatives are helping the market for regular medicines and targeted therapies for this cancer grab a bigger share.
Browse Full Report: http://www.transparencymarketresearch.com/non-small-cell-lung-cancer-market.html
Some of the important players in the global non-small cell lung cancer market are Genentech, Inc. (a Roche Company), Astra Zeneca plc, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, Novartis AG, Pfizer, Inc., and Celgene Corporation.
Angiogenesis Inhibitor Segment to Grow Rapidly in Coming Years
Targeted therapies work differently than chemotherapy drugs. Sometimes they are used in combination with chemo cycles or prescribed as standalone treatments. The precise function of these targeted drugs is to stop a process called angiogenesis, which essentially helps the tumor grow. The global non-small lung cancer (NSCLC) therapeutics market also consists of classes of drugs such as folate antimetabolites, angiogenesis inhibitors, EGFR blockers, microtubule stabilizers, kinase inhibitors, and PD-1/PD-L1 inhibitors. Of these, the angiogenesis inhibitors segment held the leading position in the market in 2014 due to its efficient results and consequently growing demand in regions such as the U.S., Japan, and Europe.
Key Drugs Used for Treating NSCLC
Bevacizumab, sold under the brand name Avastin, is an angiogenesis inhibitor used to treat an advanced form of NSCLC. This drug is usually given to the patient along with the chemotherapy cycles. It is aimed at the vascular endothelial growth factor (VEGF), which is a protein that nourishes new blood vessels. Ramucirumab, which is commercially known as Cyramza, is yet another angiogenesis inhibitor. Similar to Bevacizumab, it is a monoclonal antibody or a man-made immune system protein that is used for NSCLC. These drugs can have severe side effects such as bleeding in the lungs. Some of the other drugs in this market are Erlotinib (Tarceva), Afatinib (Gilotrif), and Gefitinib (Iressa), all of which act as epidermal growth factor receptor (EGFR) inhibitors. Commonly seen side effects of these drugs are diarrhea, skin problems, mouth sores, and loss of appetite.
Browse Press Release: http://www.transparencymarketresearch.com/pressrelease/non-small-cell-lung-cancer-market.htm
Huge Population Base in Asia Pacific to Offer Better Opportunities for Growth to NSCLC Market
In terms of geography, the global NSCLC market is segmented into North America, Asia Pacific, Europe, and Rest of the World. The modern medical amenities in North America, growing infrastructure, and efficient government systems have helped this region retain a dominating position. However, analysts predict that Asia Pacific will grow at the fastest pace in the coming years due to its huge population base, growing awareness about the disease, and increasing investment by governments to treat and eliminate diseases such as cancer.
No comments:
Post a Comment